文献速递淋巴瘤造血干细胞移植与细胞治疗

通过新方法治疗HIV相关血液系统恶性肿瘤:CAR-T细胞疗法用于癌症和HIV

CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies.
PubMed 文献 · Lancet Haematol · 2020-08-10

本文综述HIV感染者癌症负担增加及免疫治疗在该人群中的安全性和有效性证据,包括2019年抗CD19 CAR-T细胞疗法在HIV合并侵袭性B细胞淋巴瘤患者中的获批后评估显示可行性,并探讨CAR-T疗法用于治疗血液系统恶性肿瘤和HIV的新应用机会。

要点

  • HIV感染者癌症风险增加,但因社会经济因素和研究不足,其接受现代免疫治疗的机会有限。
  • HIV感染者常被排除在免疫治疗临床试验之外,2019年抗CD19 CAR-T细胞疗法获批后评估显示在该排除人群中治疗癌症的可行性。
  • 某些免疫疗法显示可减轻潜伏HIV储存库负担,CAR-T疗法有望用于治疗血液系统恶性肿瘤和HIV。

核心结论

  • 本文讨论HIV感染者癌症负担增加、免疫治疗在HIV和癌症背景下的安全性和有效性证据不断增加,以及CAR-T疗法用于治疗血液系统恶性肿瘤和HIV的新应用机会。

研究设计与样本

  • 本文为系列综述文章,检索范围未在摘要中报告。

主要发现

  • HIV感染者癌症风险增加,但社会经济因素和研究不足限制了其获得现代免疫治疗。
  • HIV感染者常被排除在癌症免疫治疗临床试验之外。
  • 2019年抗CD19 CAR-T细胞疗法在HIV合并侵袭性B细胞淋巴瘤患者中的获批后评估显示该疗法治疗癌症的可行性。
  • 某些免疫疗法显示可减轻潜伏HIV储存库负担。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

People living with HIV are a global population with increased cancer risk but their access to modern immunotherapies for cancer treatment has been limited by socioeconomic factors and inadequate research to support safety and efficacy in this population. These immunotherapies include immune checkpoint inhibitors and advances in cellular immunotherapy, particularly chimeric antigen receptor (CAR) T-cell therapy. Despite the field of cancer immunotherapy rapidly expanding with ongoing clinical trials, people with HIV are often excluded from such trials. In 2019, post-approval evaluation of anti-CD19 CAR T-cell therapy in people with HIV and aggressive B-cell lymphoma showed the feasibility of CAR T-cell therapy for cancer in this excluded group. Along with expanded treatment options for people with HIV is the ability to assess the effects of immunotherapy on the latent HIV reservoir, with certain immunotherapies showing the ability to alleviate this burden. This Series paper addresses the increased cancer burden in people with HIV, the increasing evidence for the safety and efficacy of immunotherapies in the context of HIV and cancer, and opportunities for novel applications of CAR-T therapy for the treatment of both haematological malignancies and HIV.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Rust BJ, Kiem HP, Uldrick TS, et al. CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies. Lancet Haematol. 2020. PMID: 32791043. doi:10.1016/S2352-3026(20)30142-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。